Edwards lifesciences ‍q3 adjusted eps $1.41

‍q3 sales grew 21% to $1.1 billion.‍q3 eps $1.30; q3 adjusted eps $1.41.‍q3 tavr sales of $700 million, up 26 percent.‍2019 adjusted eps guidance raised to $5.50 to $5.65 from $5.20 to $5.40.

EW Ratings Summary

EW Quant Ranking